Income Statement Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/02/2026 GMT			5-day change	1st Jan Change
8.960 ^USD	+6.67%		+25.63%	-37.91%

01-27	Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome	CI
01-20	Quoin, Inc. Announces Application for Breakthrough Medicine Designation with the SFDA for QRX003	CI

0aee726b6acefc3c0329d.1FQYhQCrbn2kGentnfHX4CUlXMBYWtpWLlcjc1qO_o0.kxtovVSaWRPNbrm-yKeamRF6KqMVLpQ3QGVaEA-2pPm6JGLMbfsUTtV_ig

Published financial data: QUOIN PHARMACEUTICALS, LTD.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Selling General & Admin Expenses, Total	1.43M	4.5M	6.58M	6.07M	5.93M
R&D Expenses	140K	1.56M	2.67M	3.31M	3.6M
Amortization of Goodwill and Intangible Assets - (IS)	104K	-	-	-	-
Other Operating Expenses, Total	1.67M	6.06M	9.26M	9.38M	9.53M
Operating Income	-1.67M	-6.06M	-9.26M	-9.38M	-9.53M
Interest Expense, Total	-47.02K	-1.37M	-714K	-	-
Interest And Investment Income	-	-	95.74K	695K	558K
Net Interest Expenses	-47.02K	-1.37M	-618K	695K	558K
Other Non Operating Income (Expenses)	-	-12.78M	78.54K	-2.68K	7.5K
EBT, Excl. Unusual Items	-1.72M	-20.21M	-9.8M	-8.69M	-8.96M
Other Unusual Items	-378K	-1.25M	416K	-	-
EBT, Incl. Unusual Items	-2.1M	-21.46M	-9.38M	-8.69M	-8.96M
Earnings From Continuing Operations	-2.1M	-21.46M	-9.38M	-8.69M	-8.96M
Net Income to Company	-2.1M	-21.46M	-9.38M	-8.69M	-8.96M
Net Income - (IS)	-2.1M	-21.46M	-9.38M	-8.69M	-8.96M
Preferred Dividend and Other Adjustments	-	-	65.27K	-	-
Net Income to Common Incl Extra Items	-2.1M	-21.46M	-9.45M	-8.69M	-8.96M
Net Income to Common Excl. Extra Items	-2.1M	-21.46M	-9.45M	-8.69M	-8.96M
Per Share Items
Net EPS - Basic	-73.34	-	-	-337.4	-66.9
Basic EPS - Continuing Operations	-73.34	-	-	-337.4	-66.9
Basic Weighted Average Shares Outstanding	28.57K	-	-	25.75K	134K
Net EPS - Diluted	-73.34	-	-	-337.4	-66.9
Diluted EPS - Continuing Operations	-73.34	-	-	-337.4	-66.9
Diluted Weighted Average Shares Outstanding	28.57K	-	-	25.75K	134K
Normalized Basic EPS	-37.56	-	-	-210.87	-41.81
Normalized Diluted EPS	-37.56	-	-	-210.87	-41.81
American Depositary Receipts Ratio (ADR)	35	35	35	35	35
Supplemental Items
EBITDA	-1.57M	-5.96M	-9.15M	-9.27M	-9.43M
EBITA	-1.57M	-5.96M	-9.15M	-9.27M	-9.43M
EBIT	-1.67M	-6.06M	-9.26M	-9.38M	-9.53M
EBITDAR	-1.57M	-	-	-	-
Normalized Net Income	-1.07M	-12.63M	-6.12M	-5.43M	-5.6M
Interest on Long-Term Debt	88	-	-	-	-
Supplemental Operating Expense Items
General and Administrative Expenses	1.43M	4.5M	6.58M	6.07M	5.93M
Research And Development Expense From Footnotes	140K	1.56M	2.67M	3.31M	3.6M
Net Rental Expense, Total	196	-	-	-	-
Stock-Based Comp., R&D Exp. (Total)	286	-	100K	152K	293K
Stock-Based Comp., G&A Exp. (Total)	452	-	664K	942K	967K
Stock-Based Comp., Other (Total)	-	-	7	549	-1.11K
Total Stock-Based Compensation	738	-	764K	1.09M	1.26M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	324K	7.48M	2.86M	2.4M	3.62M
Short Term Investments	-	-	9.99M	8.29M	10.43M
Total Cash And Short Term Investments	324K	7.48M	12.85M	10.69M	14.06M
Prepaid Expenses	-	1.02M	517K	591K	869K
Other Current Assets, Total	141K	-	-	-	-
Total Current Assets	465K	8.5M	13.37M	11.29M	14.93M
Other Intangibles, Total	913K	809K	705K	583K	483K
Other Long-Term Assets, Total	-	50K	383K	300K	300K
Total Assets	1.38M	9.36M	14.46M	12.17M	15.71M
Liabilities
Accounts Payable, Total	-	923K	606K	527K	906K
Accrued Expenses, Total	4.99M	6.54M	2.32M	2.45M	2.68M
Short-term Borrowings	1.21M	-	-	-	-
Current Portion of Long-Term Debt	-	-	600K	600K	600K
Other Current Liabilities	1.78M	865K	-	-	-
Total Current Liabilities	7.99M	8.33M	3.53M	3.58M	4.18M
Long-Term Debt	-	-	3.52M	2.92M	2.32M
Other Non Current Liabilities	-	374K	-	-	-
Total Liabilities	7.99M	8.7M	7.05M	6.51M	6.5M
Common Stock, Total	100	-	-	-	-
Additional Paid In Capital	-	31.66M	47.86M	51.87M	64.37M
Retained Earnings	-6.61M	-28.07M	-37.52M	-46.2M	-55.17M
Treasury Stock	-	-2.93M	-2.93M	-	-
Total Common Equity	-6.61M	657K	7.41M	5.66M	9.2M
Total Equity	-6.61M	657K	7.41M	5.66M	9.2M
Total Liabilities And Equity	1.38M	9.36M	14.46M	12.17M	15.71M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	28.57K	-	28.21K	105K	588K
ECS Total Common Shares Outstanding	28.57K	-	11.54K	28.21K	256K
Book Value / Share	-231.26	-	641.72	200.81	36
Tangible Book Value	-7.52M	-152K	6.7M	5.08M	8.72M
Tangible Book Value Per Share	-263.2	-	580.68	180.13	34.11
Total Debt	1.21M	0	4.12M	3.52M	2.92M
Net Debt	889K	-7.48M	-8.73M	-7.17M	-11.13M
Debt Equivalent Oper. Leases	1.57K	-	-	-	-
Account Code - Inventory Valuation	3	3	3	3	3
Full Time Employees	2	4	4	4	3
Part Time Employees	-	-	-	-	2

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	-2.1M	-21.46M	-9.38M	-8.69M	-8.96M
Depreciation & Amortization - CF	369	-	-	-	-
Amortization of Goodwill and Intangible Assets - (CF)	104K	104K	104K	104K	100K
Depreciation & Amortization, Total	104K	104K	104K	104K	100K
Amortization of Deferred Charges, Total - (CF)	-	275K	-	-	-
(Gain) Loss on Sale of Investments - (CF)	-	-	-93.78K	-489K	-252K
Asset Writedown & Restructuring Costs	-	-	-	17.52K	-
Stock-Based Compensation (CF)	-	-	764K	1.09M	1.26M
Other Operating Activities, Total	378K	14.03M	221K	-	-
Change In Accounts Payable	-	1.35M	-218K	53.92K	276K
Change in Other Net Operating Assets	274K	-18.68K	123K	41.52K	-278K
Cash from Operations	-1.34M	-5.72M	-8.48M	-7.86M	-7.86M
Investment in Marketable and Equity Securities, Total	-	-	-9.9M	2.19M	-1.89M
Other Investing Activities, Total	-125K	-625K	-250K	-	-
Cash from Investing	-125K	-625K	-10.15M	2.19M	-1.89M
Short Term Debt Issued, Total	1.98M	3.61M	-	-	-
Total Debt Issued	1.98M	3.61M	-	-	-
Short Term Debt Repaid, Total	-50K	-304K	-312K	-	-
Long-Term Debt Repaid, Total	-	-	-600K	-600K	-600K
Total Debt Repaid	-50K	-304K	-912K	-600K	-600K
Issuance of Common Stock	-	10.1M	14.88M	5.85M	11.57M
Other Financing Activities, Total	-141K	91.34K	42.04K	-32.58K	-
Cash from Financing	1.79M	13.5M	14.01M	5.22M	10.97M
Net Change in Cash	324K	7.16M	-4.62M	-459K	1.22M
Supplemental Items
Cash Interest Paid	-	394K	-	-	-
Levered Free Cash Flow	-	-3.58M	-6.21M	-4.68M	-4.28M
Unlevered Free Cash Flow	-	-3M	-5.77M	-4.68M	-4.28M
Change In Net Working Capital	-	-680K	850K	20.53K	-321K
Net Debt Issued / Repaid	1.93M	3.31M	-912K	-600K	-600K

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	-87.18	-70.6	-48.59	-44.03	-42.72
Return on Total Capital	21.07	159.99	-68.43	-56.58	-55.88
Return On Equity %	37.69	721.4	-232.68	-132.92	-120.55
Return on Common Equity	37.69	721.4	-234.3	-132.92	-120.55
Short Term Liquidity
Current Ratio	0.06	1.02	3.79	3.15	3.57
Quick Ratio	0.04	0.9	3.64	2.99	3.36
Operating Cash Flow to Current Liabilities	-0.17	-0.69	-2.4	-2.2	-1.88
Long Term Solvency
Total Debt/Equity	-18.36	-	55.68	62.21	31.76
Total Debt / Total Capital	-22.49	-	35.76	38.35	24.11
LT Debt/Equity	-	-	47.57	51.62	25.25
Long-Term Debt / Total Capital	-	-	30.56	31.82	19.16
Total Liabilities / Total Assets	579.55	92.98	48.77	53.46	41.41
EBIT / Interest Expense	-35.52	-4.44	-12.96	-	-
EBITDA / Interest Expense	-33.3	-4.36	-12.82	-	-
(EBITDA - Capex) / Interest Expense	-33.3	-4.36	-12.82	-	-
Total Debt / EBITDA	-0.77	-	-0.45	-0.38	-0.31
Net Debt / EBITDA	-0.57	1.26	0.95	0.77	1.18
Total Debt / (EBITDA - Capex)	-0.77	-	-0.45	-0.38	-0.31
Net Debt / (EBITDA - Capex)	-0.57	1.26	0.95	0.77	1.18
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	1.7	280.52	53.62	1.32	1.66
EBITA, 1 Yr. Growth %	1.7	280.52	53.62	1.32	1.66
EBIT, 1 Yr. Growth %	7.02	263.04	52.7	1.3	1.6
Earnings From Cont. Operations, 1 Yr. Growth %	34.28	924.29	-56.29	-7.41	3.18
Net Income, 1 Yr. Growth %	34.28	924.29	-56.29	-7.41	3.18
Normalized Net Income, 1 Yr. Growth %	10.04	1.08K	-51.53	-11.34	3.18
Diluted EPS Before Extra, 1 Yr. Growth %	-	-	-	-	-80.17
Total Assets, 1 Yr. Growth %	35.52	579.11	54.52	-15.83	29.09
Tangible Book Value, 1 Yr. Growth %	36.02	-97.98	-4.52K	-24.19	71.66
Common Equity, 1 Yr. Growth %	46.44	-109.94	1.03K	-23.53	62.51
Cash From Operations, 1 Yr. Growth %	3.06	327.31	48.26	-7.27	-0.09
Levered Free Cash Flow, 1 Yr. Growth %	-	-	-18.6	-24.62	-8.73
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-	-18.25	-18.79	-8.73
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	-	96.73	141.77	24.76	1.49
EBITA, 2 Yr. CAGR %	-	96.73	141.77	24.76	1.49
EBIT, 2 Yr. CAGR %	-	97.12	135.45	24.37	1.45
Earnings From Cont. Operations, 2 Yr. CAGR %	-	270.87	111.6	-36.38	-2.26
Net Income, 2 Yr. CAGR %	-	270.87	111.6	-36.38	-2.26
Normalized Net Income, 2 Yr. CAGR %	-	259.91	138.87	-34.44	-4.36
Total Assets, 2 Yr. CAGR %	-	203.37	223.94	14.04	4.24
Tangible Book Value, 2 Yr. CAGR %	-	-83.44	-5.59	478.96	14.07
Common Equity, 2 Yr. CAGR %	-	-61.84	5.88	193.61	11.48
Cash From Operations, 2 Yr. CAGR %	-	109.86	151.7	17.26	-3.75
Levered Free Cash Flow, 2 Yr. CAGR %	-	-	-	-21.67	-17.06
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	-	-	-18.52	-13.91
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	-	-	81.16	80.93	16.53
EBITA, 3 Yr. CAGR %	-	-	81.16	80.93	16.53
EBIT, 3 Yr. CAGR %	-	-	81.03	77.75	16.26
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	81.84	60.64	-25.26
Net Income, 3 Yr. CAGR %	-	-	81.84	60.64	-25.26
Normalized Net Income, 3 Yr. CAGR %	-	-	84.48	71.67	-23.74
Total Assets, 3 Yr. CAGR %	-	-	142.27	106.71	18.85
Tangible Book Value, 3 Yr. CAGR %	-	-	6.63	-12.25	286.06
Common Equity, 3 Yr. CAGR %	-	-	17.97	-5.01	141.07
Cash From Operations, 3 Yr. CAGR %	-	-	86.91	80.44	11.16
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	-	-	-17.57
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	-	-	-15.38
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	-	-	-	-	43.68
EBITA, 5 Yr. CAGR %	-	-	-	-	43.68
EBIT, 5 Yr. CAGR %	-	-	-	-	43.6
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	-	41.85
Net Income, 5 Yr. CAGR %	-	-	-	-	41.85
Normalized Net Income, 5 Yr. CAGR %	-	-	-	-	41.85
Total Assets, 5 Yr. CAGR %	-	-	-	-	72.9
Tangible Book Value, 5 Yr. CAGR %	-	-	-	-	9.55
Common Equity, 5 Yr. CAGR %	-	-	-	-	15.33
Cash From Operations, 5 Yr. CAGR %	-	-	-	-	43.33